# MARKET_RESEARCH_LOG_2026-08-26

> Production GenGe V3.1.1 hourly scan handoff. Repository `main` remains the source of truth. This log records completed production artifacts and is not an automatic trading instruction.

## GenGe V3.1.1 production promotion and current-date dry-run

- Production decision: `PROMOTE_CONFIDENCE_GATE_ONLY`.
- Current version: `GEN_GE_V3_1_1_PRODUCTION`.
- Round 8 discovery passed all frozen thresholds. Round 9 confirmed PIT, confidence, Sharpe, drawdown, CAGR and cash requirements; full V3.2 was rejected because its 12-month SELL opportunity cost exceeded the frozen limit.
- The original immediate V3.1 SELL ladder remains active. LOW/INVALID valuation confidence now forces HOLD_REVIEW; Hard Gate FAIL still forces EXIT.
- The original current-date dry-run and earlier intraday scans are retained in git history. No Round 10 or V3.3 is authorized.

## Prior runs retained

01:10, 03:06, 05:06, 06:09, 07:08, 12:08, 13:08, 14:11, 15:07, 16:06 and 17:10 CST scans are retained by the durable ledger/history. Formal BUY remained NONE. `603658 安图生物` remained the only execution-eligible durable deep-research candidate; its 2026H1 attributable profit -12.94% YoY, operating cash flow -47.38% YoY and capacity-project reallocation remain controlling blockers.

---

## 2026-08-26 19:07 CST — opportunity + full CURRENT_HOLDINGS risk refresh

### Fresh-data / production guardrails

- Re-read current `main` `AGENTS.md`, `CURRENT_HOLDINGS.md`, `V31_CANDIDATE_LEDGER.md`, `CURRENT_MARKET_RESEARCH.md`, `RESEARCH_QUEUE.md`, `MODEL_EVOLUTION_LOG.md` and today's durable market log. Current repository rules remain controlling.
- `603658 安图生物`: public sources now consistently observe ~33.48–33.49 during 2026-08-26, but the company IR quote remains internally inconsistent and a second independently accepted 15:00 close was not recovered. Therefore the execution-grade accepted close remains 34.17 on 2026-08-25 and **Formal BUY/ADD remains blocked**.
- No new execution-eligible A1/A2 candidate was established. `603658` remains WAIT / Formal BUY = NO.

### Candidate delta

- `603658 安图生物`: **RESEEN / PRICE_OBSERVED_ONLY**; last_seen -> 19:07 CST; seen_count -> 12. H1 earnings/cash-flow weakness, incomplete normalized Bear/Base/Bull valuation and the unresolved capacity-expansion-to-R&D capital-allocation signal remain controlling blockers. No tier, valuation or entry-band upgrade.

### Holdings-risk review

- **600879 航天电子: REDUCE — NEW MATERIAL HOLDING RISK.** 2026H1 revenue 45.30亿元, -22.19% YoY; attributable profit 4058.92万元, -76.63%; deduct-profit 2272.40万元, -84.90%; operating cash flow remains deeply negative at -23.46亿元. This is not a one-period ordinary fluctuation: H1 revenue had already fallen about 20% in 2024 and 24.5% in 2025, while H1 attributable profit fell about 35.8%, 30.4% and now 76.6% across 2024–2026. The company attributes the current decline to product delivery progress below expectation and lower pricing on some products. Long-term aerospace-electronics/unmanned-system demand and technical/qualification moat are **not** judged invalidated; overseas unmanned-system orders/receipts are still described as improving. However, sustained delivery/earnings deterioration plus price pressure creates a negative expectation gap. Fresh 2026-08-26 close is **14.23 CNY** (15:00:02), flat on the day; reported TTM PE is about **205x**, versus the referenced industry median around 50x. Under V3.1 this produces a **REDUCE**, not EXIT: de-risk exposure until delivery normalization and earnings quality are demonstrated. **REDUCE trigger:** sustained revenue/profit contraction + product pricing pressure + valuation far above earnings support. **Escalate to EXIT if:** H2/next report confirms continued delivery weakness or pricing erosion, core order/market-share/qualification moat deteriorates, or normalized Bear/Base value remains materially below market after refreshed valuation. **Cancel REDUCE / return HOLD if:** delivery slippage is demonstrably temporary, H2 revenue/deduct-profit recover materially with cash conversion, and refreshed normalized valuation restores a positive expectation gap.
- `003816 中国广核`: **HOLD**. 2026H1 revenue -2.76% YoY but attributable profit +2.66%; no hard thesis break found. Nuclear long-term demand/asset moat remains intact.
- `600900 长江电力`: **HOLD**. Latest relevant disclosure is controlling-shareholder accumulation through 2026-08-22; no new thesis-break evidence found in this interval.
- `600795 国电电力`, `601985 中国核电`, `600674 川投能源`, `600905 三峡能源`, `601872 招商轮船`, `600026 中远海能`, `600938 中国海油`, `002053 云南能投`, `600312 平高电气`, `600089 特变电工`, `600875 东方电气`, `601899 紫金矿业`, `600522 中天科技`, `601012 隆基绿能`, `601919 中远海控`, `600071 凤凰光学`, `600118 中国卫星`, `600893 航发动力`: **HOLD / HOLD_REVIEW as previously applicable; no newly verified 2026-08-26 evidence in this interval was sufficient to create an additional REDUCE/EXIT.** Ordinary price movement and personal cost basis were not used as sell triggers.

### Delta / notification decision

- **Ledger:** `603658` RESEEN; PRICE_OBSERVED_ONLY; no BUY upgrade.
- **NEW / UPGRADED candidate:** none.
- **Formal BUY / ADD:** NONE.
- **Holding risk:** `600879 航天电子` **NEW REDUCE**.
- **Production/data status:** no CI/production-chain failure established. Fresh-price invariant correctly continues to fail closed for `603658` Formal BUY.
- **Notification trigger:** YES — holding-level REDUCE risk on `600879 航天电子`.
